Table 2

Effect of chronic resveratrol (resv) treatment on the metabolic profiles of NASH mice

Ctrl (n=5)NASH (n=9)NASH-resv (n=9)NASH-resv-EX527 (n=9)
(Triglyceride, TG, mg/dL)55±4.8209±28*124±17167±9
(Fasting glucose) (mg/dL)99±8189±21*118±16158±13
(Fasting insulin) (ng/mL)1.4±0.095.8±0.68*3.4±0.784.7±0.42
HOMA-IR index2.4±0.118.8±2.1*6.9±1.312.8±0.8
(Aspartate aminotransferase) (AST, U/L)52.3±4.9145.7±5.2*98.5±11.4114.8±10.3
(Alanine aminotransferase) (ALT, U/L)49.1±7.1120.3±20.1*84.4±9.6††114.5±1.6
Hepatic hydroxyproline content (μg/mg liver weight)0.19±0.020.79±0.07*0.35±0.020.64±0.03
  • Ctrl/NASH/NASH-resv: mice receiving 12 week of high-fat diet (HFD)+MCD diet or normal chow (NC) feeding and vehicle or resv (resveratrol, 30 mg/kg/day) treatment for 6 week from the 7th to 12th weeks of HFD+MCD feeding; NASH-resv+EX527: NASH mice are concomitant receiving resveratrol and EX-527 (SIRT1 inhibitor) treatment. HOMA-IR: homeostasis model assessment-insulin-resistance, calculated as ((fasting glucose)×(fasting insulin))/58.32.

  • *p<0.05 vs Ctrl group.

  • p<0.05 vs NASH group.

  • HOMA-IR, homeostasis model assessment-insulin-resistance; MCD, methionine and choline deficient; NASH, non-alcoholic steatohepatitis.